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 Chikungunya (CHIK) is a disabling and debilitating zoonotic disease of humans 
caused by the Chikungunya virus (CHIKV); it is transmitted by infected Aedes spp 
mosquitoes, which sustain sylvatic and human rural and urban CHIK cycles.  
 Chikungunya is listed on the WHO Blueprint priority pathogens because in the past 5 
years an alarming and unprecedented increase in spread to over 100 countries across 
Asia, Africa, Europe, and the Americas.  
 The incubation period of between 1 and 12 days is followed by symptoms similar to 
dengue, Zika, parvovirus, enterovirus, malaria, with an abrupt onset of high fever, 
nausea, polyarthralgia, myalgia, widespread skin rash, and conjunctivitis.  
 Serious complications include myocarditis, uveitis, retinitis, hepatitis, acute renal 
disease, severe bullous lesions, meningoencephalitis, Guillain-Barre´ syndrome, 
myelitis, and cranial nerve palsies. Severe disease occurs in neonates exposed during 
pregnancy, the elderly, and those with comorbid diabetes, renal, liver, and heart 
disease.  
 Treatment is supportive and there is no specific antiviral treatment and no effective 
vaccines. 
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Tü bingen, Germany; f Center for Clinical Microbiology, University College London, Royal Free 
Campus 2nd Floor, Rowland Hill Street, London NW3 2PF, United Kingdom 
* Corresponding author. 
E-mail address: francesco.vairo@inmi.it  
 
 
 
INTRODUCTION 
 
Chikungunya (CHIK) is a disabling and debilitating zoonotic disease of humans caused 
by the Chikungunya virus (CHIKV), which is transmitted by CHIKV-infected Aedes spp 
mosquitoes (Fig 1). The primary CHIKV reservoir hosts are nonhuman primates.1 Chi- 
kungunya is listed on the WHO Blueprint priority pathogens (https://www.who.int/ 
blueprint/en/) because in the past 5 years, an alarming and unprecedented increase 
in spread has occurred with cases reported from more than  100 countries across  the 
Americas, Africa, Europe, and Asia, affecting millions of people (Fig. 2). 
 
HISTORICAL 
 
CHIKV most likely originated in East and central Africa where the virus is endemic to a 
sylvatic cycle between mosquitoes and nonhuman primates living in forests. In 1952, 
CHIK was described during an outbreak on the Makonde plateau in southern Tanzania 
on the border with Mozambique.2 CHIKV was isolated from the serum of a febrile patient 
during an outbreak of an exanthematous febrile disease. Soon after in 1953, CHIKV was 
isolated in mosquitoes of the Aedes aegypti (Ae aegypti), and the virus was placed in 
arbovirus group A.3 There are remarkable similarities between the clinical syndromes 
caused by dengue virus and CHIKV.4 Before the discovery of CHIKV, cases were mostly 
diagnosed and treated as malaria or dengue. The actual name Chikungunya is derived 
from the Makonde tribe (Kimakonde language) meaning "that which bends up" or “to 
become contorted,” which describes the stooped bent posture of patients with CHIKV 
who develop joint pain (Virusnet.com). The virus is maintained in a complex sylvatic and 
rural cycle, progressing to an urban cycle every 5 to 20 years, causing global pandemics 
(Fig. 3). Following discovery of CHIK in Tanzania, it was identified in Uganda and sub- 
sequently in many other sub-Saharan African countries5 with global spread in the 
ensuing years (see Fig. 2). These CHIKV strains were grouped in a single lineage and 
named after the geographic location as East, Central and South Africa (ECSA) CHIKV 
lineage. A different monophyletic group was identified during outbreaks in Asia from 
1958 to 1973 and called Asian CHIKV lineage.6,7 These different geographic genotypes 
exhibit differences in their transmission cycles. In Asia, the CHIKV seems to be main- 
tained in an urban cycle with Ae aegypti mosquito vectors, whereas CHIKV transmission 
in Africa involves a sylvatic cycle, primarily with Ae furcifer and Ae africanus mosquitoes. 
A distinct CHIKV clade, the West Africa lineage, was isolated from West Africa, and this 
 
 
Fig. 1. Mosquito vector of CHIKV: female Aedes aegypti mosquito. A close-up lateral view of 
the female Aedes aegypti mosquito from a left lateral perspective, feeding on the human 
host with distended abdomen filled with host blood. (Courtesy of US-CDC, Public Health Im- 
age Library (PHIL) https://phil.cdc.gov/Details.aspx?pid59260.) 
 
 
 
Fig. 2. World map showing countries and territories reporting CHIKV. (Data from The Cen- 
ters for Disease Control: https://www.cdc.gov/chikungunya/geo/index.html.) 
 
 
 
Fig. 3. The transmission cycles of Chikungunya virus as described in Althouse et al (2018). A) 
The sylvatic cycles of Chikungunya virus exists primarily in Africa between non-human pri- 
mates, rodents and possibly in bats and forest-dwelling Aedes species (Ae. albopictus, Ae. 
furcifer, Ae africanus, Ae. taylori). B) The rural transmission occur when rural population 
bitten by infected forest-dwelling mosquitoes, especially by Ae albopictus. C) Movement   of 
infected humans can result in establishment of a large urban transmission through urban 
Aedes mosquitoes (Ae. aegypti and Ae. albopictus), where a human-mosquito-human cycle 
is established. Ae. albopictus feeds on a range of hosts including humans and wild mammals 
whereas Ae. aegypti primarily feeds on human, and most forest dwelling Aedes species (Ae. 
furcifer, Ae africanus, Ae. taylori) feeds primarily on animals. (Date from Althouse, B. M. et 
al. Role of monkeys in the sylvatic cycle of chikungunya virus in Senegal. Nat. Commun. 
(2018); and adapted from Petersen, L. R., Stramer, S. L. & Powers, A. M. Chikungunya Virus: 
Possible Impact on Transfusion Medicine. Transfus. Med. Rev. (2010); with permission.) 
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has been circulating in the past 30 years. The 2 major enzootic CHIKV lineages in Africa 
were introduced from eastern Africa into Asia between 1920 and 1950. The more recent 
Indian Ocean and Indian epidemic CHIKV strains emerged independently from the 
mainland of East Africa.8 This lineage has been called the Indian Ocean Lineage (IOL) 
and has been repeatedly associated with outbreaks from 2005 to 2014.8,9 
 
EPIDEMIOLOGY 
The Chikungunya Virus 
Phylogenetic analysis has shown 4 different genotypes of CHIKV based on geographic 
regions: the west African genotype (Senegal and Nigeria), the ECSA genotype, the 
Asian genotype, and the IOL genotype.4,6,7,10 CHIKV is an enveloped, spherical, 
single-stranded positive-sense RNA alphavirus belonging to the family Togaviridae.  It 
has a genome size of w12 kb, and it consists of 2 open reading frames cleaved into 4 
nonstructural proteins (nsP1, nsP2, nsP3, and nsP4)11 and 5 structural proteins (C, E3, 
E2, 6K, and E1).12 E1 and E2 are surface glycoproteins, 439 and 423 amino acids 
long, respectively.13 E1 and E2 carry the major viral epitopes and participate   in the 
attachment and the entry of the virus into target cells, where E2 is responsible for 
receptor binding and E1 for membrane fusion.14 E3 consists of 64 amino acids that are 
required for E3-E2-6K-E1 or E3-E2-TF polyprotein translocation into the endo- plasmic 
reticulum for virus spike formation.15 The 6K protein is a cation-selective    ion channel 
that causes increased cell permeability to monovalent cations and virion budding 
during infection.16 Transframe protein TF is produced as a result of C-terminal extension 
of 6K protein in the 1 frame.17 It retains ion-channel activity similar to that of 6K and 
seems to be important for assembly and release of the virus particle.17 Although the 
nonstructural proteins nsP1-nsP4 are primarily associated with the viral replication 
process,18,19 they have additional functions during the viral infection, just like in other 
alphaviruses.20 Nonstructural proteins are not packaged into the final vi- rions, and 
hence the structural proteins (mainly surface glycoproteins E2 and E1) are the key 
targets of the host humoral immune response and of most CHIK vaccines.21 
 
Global Distribution, Transmission, and Chikungunya Virus Outbreaks 
Human cases of CHIK have been reported from all continents affecting males and fe- 
males of all age groups. The CHIKV circulates between mosquitoes and naive human 
hosts in cyclical form similar to dengue viruses. Until 5 years ago, most CHIK cases 
were reported from Africa, Asia, Europe, and the Indian and Pacific Oceans. Interna- 
tional travel led to the spread of CHIKV to Europe and focused global attention.22 The 
first local transmission of CHIKV in the Americas was identified in Caribbean countries 
and territories in 2013 and subsequently spread rapidly throughout the Americas23 
(see Fig. 2). To date, human cases of CHIK have been found in more than 100 coun- 
tries (Table 1). 
Large outbreaks were reported in Comoros in 2005 with approximately 215,000 
cases24 and in Reunion Island between March 2005 and April 2006 with 255,000 
cases.25 The spread of CHIKV to the islands of the Indian Ocean, India, and Southeast 
Asia after a large outbreak in Kenya in 2004 has been a key factor in focusing global 
attention. Selected outbreaks in various countries are listed in Table 2. CHIKV subse- 
quently spread beyond its original tropical locations in Africa and the Indian subcon- 
tinent, becoming a serious emerging issue in temperate regions of Europe and the 
Americas with autochthonous small outbreaks occurring as a consequence of spill- 
over from endemic tropical areas in continental Europe: Italy in 2007, and in France in 
2010, in 2014, and 2017.26–29 In 2017, a major outbreak in Italy was concentrated 
 
Table 1 
Countries where CHIKV human infections have been reported 
Continent Country 
Africa • Angola 
• Benin 
• Burundi 
• Cameroon 
• Central African Republic 
• Comoros 
• Cote d’Ivoire 
• Democratic Republic of the 
Congo 
• Djibouti 
• Equatorial Guinea 
• Gabon 
• Guinea 
• Kenya 
• Madagascar 
• Mauritius 
• Mayotte 
• Mozambique 
• Nigeria 
• Republic of the Congo 
• Reunion 
• Senegal 
• Seychelles 
• Sierra Leone 
• South Africa 
• Somalia 
• Sudan 
• Tanzania 
• Uganda 
• Zimbabwe 
  • Malawi  
Asia • Bangladesh 
• Bhutan 
• Cambodia 
• China 
• India 
• Indonesia 
• Laos 
• Malaysia 
• Maldives 
• Myanmar (Burma) 
Europe • France 
• Italy 
• Nepal 
• Pakistan 
• Philippines 
• Saudi Arabia 
• Singapore 
• Sri Lanka 
• Thailand 
• Timor-Leste 
• Vietnam 
• Yemen 
 
  • Spain  
Americas • Anguilla 
• Antigua and Barbuda 
• Argentina 
• Aruba 
• Bahamas 
• Barbados 
• Belize 
• Bolivia 
• Brazil 
• British Virgin Islands 
• Cayman Islands 
• Colombia 
• Costa Rica 
• Cuba 
• Curacao 
• Dominica 
• Dominican Republic 
• Ecuador 
• El Salvador 
• French Guiana 
• Grenada 
• Guadeloupe 
• Guatemala 
• Guyana 
• Haiti 
• Honduras Jamaica 
• Martinique 
• Mexico 
• Montserrat 
• Nicaragua 
• Panama 
• Paraguay 
• Peru 
• Puerto Rico 
• Saint Barthelemy 
• Saint Kitts and Nevis 
• Saint Lucia 
• Saint Martin 
• Saint Vincent and the 
Grenadines 
• Sint Maarten 
• Suriname 
• Trinidad and Tobago 
• Turks and Caicos Islands 
• Venezuela 
• United States 
• US Virgin Islands 
   
(continued  on next page) 
 
 
Table 1 
(continued ) 
Continent 
Oceania/Pacific 
Islands 
 
• American Samoa 
• Cook Islands 
• Federal States of 
• Fiji 
• French Polynesia 
• Kiribati 
 
 
 
 
Micronesia 
Country 
• Marshall Islands 
• New Caledonia 
• Papua New Guinea 
• Samoa 
• Tokelau 
• Tonga 
(Courtesy of The Centers for Disease Control: https://www.cdc.gov/chikungunya/geo/index.html.) 
 
 
around 3 main foci (Anzio, Rome, Guardavalle Marina) in 2 different regions, Lazio 
(Anzio, Rome) and Calabria (Guardavalle Marina), in Central and Southern Italy.30 
Phylogenetic analysis showed that the CHIKV from the Lazio outbreak belonged to 
the ECSA clade and clusters within the IOL.31 
In Africa, CHIKV epidemics have been reported from Central African Republic, 
Guinea, Burundi, Angola, Uganda, Malawi, Nigeria, Democratic Republic of the Congo, 
South Africa, and Nigeria. In June 2004 in an outbreak that occurred  in Lamu Atoll, 
Kenya, and spread to Mauritius, Seychelles, Comoros, and Reunion Is- land, almost 
half a million cases were reported. Several other epidemics occurred in all 
southwestern Indian Ocean islands except Madagascar from 2005 to 2007. In 2011, a 
CHIKV epidemic occurred in the Democratic Republic of the Congo (317 cases), Pool 
(460 cases), and Brazzaville (7014 cases). 
 
 
 
Table 2 
Major global outbreaks of CHIKV 
 
Year Country 
1954 United Republic of Tanzania 
1999–2000 Democratic Republic of Congo 
2005 to date Islands of the Indian Ocean 
Maldives 
India 
Myanmar 
  Thailand  
2006–2007 India 
2007 Gabon 
2007 Italy 
2011 Republic of Congo 
2013 France 
2014 Pacific Islands (Cook, Marshall, and others) 
2015 Americas 
2016 Pakistan 
2017 Italy 
2017 Kenya 
2019 Republic of Congo 
2019 Democratic Republic of Congo 
 
 
Mosquito Vectors 
In Africa, CHIKV circulates in an enzootic cycle between forest-dwelling Aedes spp 
mosquitoes (Ae furcifer, Ae taylori, Ae africanus, Ae luteocephalus) and is main- tained 
in nonhuman primates and other  vertebrate  reservoirs  such  as  rodents  and bats 
(see Figs. 1 and 3).1,32,33 The primary CHIKV reservoir hosts  are  nonhuman primates, 
and the 5- to 10-year periodicity of CHIKV transmission may depend on oscillations in 
monkey herd immunity.1 In Senegal, enzootic strains of CHIKV have been isolated 
from diverse species of mosquito including Ae (Dicero- myia) furcifer, Ae (Diceromyia) 
taylori, Ae (Stegomyia) luteocephalus, Ae (Stegomyia) africanus, and Ae (Stegomyia) 
neoafricanus.1 Sporadic spillover of enzootic CHIKV into urban interhuman 
transmission cycles is amplified by the involvement of anthropophilic mosquito species 
such as Ae (Stegomyia) aegypti and Ae (Stego- myia) albopictus.34 
The behavior and ecology of Ae aegypti makes it an ideal vector during epidemic 
cycles because of its anthropophilic nature. Moreover, adult females often take several 
blood meals during a single gonotrophic cycle, and artificial containers are preferred 
larval sites.35 Ae albopictus mosquitoes are both zoophilic and anthropo- philic and 
are active throughout the day. In Asia, CHIKV is maintained in an urban transmission 
cycle vectored by the mosquito Ae aegypti and Ae albopictus.8. Ae albo- pictus, the 
Asian tiger mosquito, was discovered in 1894 in India and is endemic to Southeast 
Asia. Ae albopictus mosquitoes have successfully colonized all 5 conti- nents 
throughout both temperate and tropical regions.36 It has successfully spread because 
of its ability to thrive in arid and cold conditions, undergo periods of adult  diapause, 
and overwinter by laying desiccation-resistant eggs. Although these mosquitoes do not 
have a specific ecological niche, distinct temperate and tropical populations have 
arisen. CHIKV circulation typically coincides with periods of heavy rains and increased 
density of mosquito.37 The urbanization and human migration from rural to urban areas 
has led to the introduction of Ae aegypti and Ae albopictus living around human 
habitations, sustaining CHIKV transmission in a mosquito-human cycle. 
 
Chikungunya Virus Mutations and Infectivity 
The E1-A226V mutation has resulted in a dramatic increase in the infectivity of CHIKV, 
and the transmission of CHIKV has spread to Europe and the Americas facilitated by 
widespread distribution of the Aedes spp vectors. The nonsynonymous mutation in the 
E1 glycoprotein of the viral envelope (E1-A226V) was identified in 90% of isolates 
during the outbreak in Reunion Island in 2006.38 This mutation is important for viral 
fitness in Ae albopictus, although the mutation does not affect viral replication in Ae 
aegypti.39,40 This adapted variant was involved in outbreaks in north-eastern Italy in 
2007 and in south-eastern France in 2014 and 2017, where Ae albopictus is wide- 
spread.27,41,42 Thus, although Ae aegypti was widely recognized as the main urban 
vector of CHIKV in tropical areas, Ae albopictus is considered able to transmit CHIKV 
in temperate climate areas too. Mosquito studies highlighted the role of Ae albopictus 
as a CHIKV vector during the European outbreaks 26, 27, and experimental infection 
confirmed a high susceptibility of local European Ae albopictus populations to the 
mutated ECSA CHIKV strain. Other less widespread mutations are believed to in- 
crease initial infection in Ae albopictus midgut cells, all of them in the IOL lineage. E2-
K252Q, E2-K233E, E2/E3-R198Q/S18F, and E2-L210Q affect the initial infection of 
the Ae albopictus midgut cells with major effects on infection of Ae aegypti.43    The 
same mutations are predicted to affect CHIKV Asian lineages circulating in the 
 
 
Americas as a result of a so-called founder effect and resultant epistasis. The amino 
acid mutation A98T in E1 protein in the Asian lineage prevents penetrance for Ae albo- 
pictus infection.8,44 
 
MODES OF CHIKUNGUNYA VIRUS TRANSMISSION 
 
There   are   several   ways   in   which   CHIKV   is   acquired   by   humans.45 
CHIKV is transmitted to people through bites from Ae aegypti, Ae albopictus, and Ae 
polynesienses mosquitoes, the same mosquitoes that transmit the dengue virus. 
These mosquitoes breed in or near human habitations and prefer to feed on humans 
during the daytime in shady areas and early in the evening. Horizontal transmission in 
Aedes spp can occur and contribute to the maintenance of CHIKV cycles.46 Vertical 
transmission is rare but has been observed under natural and experimental condi- 
tions.47–49 In Africa, CHIKV circulates primarily in an enzootic cycle, with occasional 
spillover infections of humans. 
Coinfection with dengue virus and CHIKV,50 and CHIKV with dengue virus, Zika vi- 
rus, yellow fever virus, and West Nile virus have been described.51 
Iatrogenic Transmission 
To date, no studies on transfusion-transmitted CHIKF from viremic donors to recip- 
ients has been published. There is increasing concern that CHIKV might be trans- 
mitted by way of transfusions given its high-level viremia attack rate during  outbreaks 
and a significant proportion of asymptomatic infections. Viremic asymp- tomatic52 
CHIKV-infected cases have shown high potential as disseminators of transfusion-
associated CHIKF, because CHIKV levels capable of inducing CHIKF were found in 
the blood of asymptomatic cases during the 2009 epidemic in Songkhla, Thailand.52 
As with other arboviruses, several factors determine the impact of CHIKV on 
transfusion medicine: (1) prevalence of viremia among blood donors, (2) proportion of 
components derived from viremic donations that transmit infection to recipients, (3) 
clinical impact on infected transfusion recipients, (4) availability of measures to reduce 
transfusion transmission when required, and 
(5) the cost and disruption incurred by those  measures.  Several  models  have been 
applied to estimate the risk of transfusion-associated HIKV  transmission. Model 
results from Reunion Island53 and Thailand52 indicate  a  significant  short- term risk of 
transfusion-associated CHIKV transmission during large outbreaks, whereas the 
Italian model suggests a small, but quantifiable risk that may exceed accepted safety 
standards during smaller, focal outbreaks54 that may occur in temperate areas. 
Few cases of CHIKV infection in solid-organ transplant (SOT) recipients have been 
reported.55–57 In a case series from Brazil, 13 SOT recipients (9 kidney, 4 liver) infected 
with CHIKV showed similar clinical presentation to immunocompetent hosts, including 
chronic joint symptoms in 46%. However, there were no complications or deaths, and 
these transplant patients experienced no apparent damage to the graft. In addition, 
infectious CHIKV can be isolated from corneal grafts from both symptomatic and 
asymptomatic donors, although no cases transmitted by corneal transplant have been 
reported to date.58 SOT recipients who travel to or live in CHIKV endemic areas are at 
high risk of acquiring the disease. 
Maternal-fetal transmission has been reported.  Intrapartum  contamination  without 
actual placental infection has been well documented for  CHIKV  virus,  which is not 
able to infect the placenta.59,60 CHIKV is not transmitted to the fetus      in the absence 
of placental breaches, which allow transfer of maternal blood to the 
 
 
fetal circulation.59 A recent meta-analysis61 estimated a pooled mother-to-child 
transmission risk across the analyzed cohorts of 15.5%, with the highest  risk  among 
infections in the intrapartum period (12 days from delivery). During intra- partum 
viremia, the vertical transmission rate of CHIKV is reported as 48.7%. Mothers who 
have a high viral load in their placenta are more likely to transmit       the virus.59 There 
is no evidence of CHIKV transmission by way of breast milk to infants.62 
CHIKV has been detected in semen 30 days after symptom’s onset,63 indicating 
possible sexual transmission. No evidence of sexual transmission between humans 
has been reported so far. 
 
PATHOGENESIS 
 
During the first week of  infection,  CHIKV  can  be  found  in  the  blood  and  can  be 
passed from an infected  person  to  a  mosquito  through  mosquito  bites.  CHIKV 
has certain cell types that are particularly susceptible to infection; these include human 
epithelial and endothelial cells, primary fibroblasts, and monocyte-derived 
macrophages.64 Lymphoid and monocytoid cells, primary lym- phocytes and 
monocytes, and monocyte-derived dendritic cells did not  demon- strate CHIKV 
replication.65 The human skin is the first site  of  viral  replication, mainly in the dermal 
fibroblasts. From  here,  the  virus  enters  the  lymph  nodes and the circulatory system, 
disseminating to all organs.66 During the acute and subacute phases, CHIKV reaches 
muscle and joint compartments: primary muscle fibroblasts and skeletal muscle 
fibroblasts, and both have been found to be permissive.60,67 
Chikungunya clinical syndrome is characterized by arthralgia, which is usually 
symmetric and affects distal synovial joints more than proximal joints.68 In patients, 
during acute and persistent arthralgia CHIKV RNA and proteins have been found in 
synovial tissue and fluids, with synovial fibroblasts and macrophages susceptible to 
the infection.60,68,69 Infected macrophages are the preferred site for viral replication, 
contributing to viral persistence and chronic symptoms.68 The  presence  of increased 
levels of cartilage bioproducts in urine70 and low plasma levels of hepa- tocyte growth 
factor in chronic patients71 indicate connective tissue alterations and cartilage damage. 
CHIKV replicates actively and persists in the osteoblasts.69,72 Bone loss is a 
characteristic of CHIK-associated arthritis. The pathogenesis of persistent symptoms 
after CHIK infection is still unclear.  CHIKV  proteins  have  been detected in 
macrophages and muscle cells of patients with relapse of chronic pain, suggesting 
that low replicative viruses or nonreplicative CHIKV debris may persist. A persistent 
immune activation has been detected in mouse models.73,74 Immune and inflammatory 
responses to CHIKV infection may also contribute to pathogenesis.75,76 
Neurologic manifestations have often been reported in several outbreaks, with    an 
increasing number of cases with neurologic complications after the  reemer- gence of 
CHIKV in the Indian Ocean in 2005. The virus has frequently been isolated from 
cerebrospinal fluid (CSF).77 The target cells for CHIKV in the human brain remain 
unknown. In vitro infection of human cells have demonstrated the suscep- tibility of 
neuroblastoma cells,78 microglial cells,79 and glial cells, such as astro- cytes,80 showing 
signs of apoptosis. Nevertheless, it is still unclear if the pathogenesis of the nervous 
system  is  directly  connected  with  the  infection  of the neurons and glial cells or is 
indirectly connected triggering the immune-  mediated effects. 
 
 
CLINICAL FEATURES 
Incubation Period 
The incubation period can vary from 1 to 12 days (average, 2–7 days). CHIKV infec- 
tion causes high levels of viremia, which usually last for 4 to 6 days after the onset  of 
symptoms. CHIKV infection is symptomatic in most children and adults who are 
infected, with less than 15% having asymptomatic sero-conversion.53 
Symptoms 
The symptoms (Table 3) are similar to those of other arboviruses, such as dengue and 
other common causes of febrile illnesses in the tropics; thus, accurate diagnosis is 
challenging. 
During the acute phase of illness, the intensity of the clinical symptoms correlates 
with the viremia during the acute infection, usually lasting 1 week when anti-CHIKV 
IgM antibodies appear.81 Following the onset of fever, intense myalgia and arthralgia 
occur. These symptoms can be severe and disabling, causing much morbidity. 
 
 
Table 3 
Clinical features of Chikungunya: symptoms and signs 
 
Stage Signs and Symptoms 
Acute stage Common 
Fever 
Macular to maculopapular rash 
edema of the face and extremities 
Benign bleeding (gingival bleeding, epistaxis) in children 
Pruritus 
Myalgia  
Arthralgia 
Periorbital pain 
Headache 
Lymphadenopathy 
Less common 
Diarrhea, vomiting, abdominal pain 
Confusion 
Optical neuritis 
Oral or gingival ulceration 
   Conjunctivitis  
Post-acute stage Inflammatory arthralgia, joint stiffness 
Arthritis (synovitis with or without effusion) 
Tenosynovitis, bursitis 
Decompensation of pre-existing degenerative or traumatic arthropathy 
Osteoarthritis or sometimes-calcific tendinitis 
Entrapment syndromes 
Neuropathic pain 
Severe asthenia 
  Neuropsychological disorders  
Chronic stage Joints: articular arthritis, synovitis, degenerative osteoarthritis, bursitis 
Tendons: tendinitis, enthesitis, tenosynovitis 
Edema 
Neuropathic pain 
Stiffness 
Loss of physical fitness 
Postural hypotension 
Mood disorders 
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Disabling polyarthralgia is a key symptom for differential diagnosis with a positive pre- 
dictive value greater than 80%.82 The joint pain is usually symmetric in both the arms 
and legs; the large joints are almost invariably symptomatic. Other common signs are 
nausea, fatigue, headache, back pain, and skin rash (50% of cases). The skin lesions 
are characterized by a macular or maculopapular transitory eruption often in the body 
extremities, palms, soles of the feed, torso, and face.81,83 Gastrointestinal tract 
involvement can manifest as nausea, vomiting, and abdominal pain.84 Ocular manifes- 
tations can occur during the acute phase with photophobia, retro-orbital pain, and 
conjunctivitis.85 
The acute phase is usually followed by a post-acute stage, usually from the fourth 
week to the end of the third month.86 This phase is characterized by persistence of the 
initial inflammatory events, including inflammatory arthralgia, arthritis (synovitis with or 
without effusion), tenosynovitis, bursitis, which slowly regress. It is often asso- ciated 
with decompensation of pre-existing degenerative or traumatic arthropathy 
(sometimes unknown) such as osteoarthritis or calcific tendinitis, and local events such 
as reactionary edema, entrapment syndromes, joint stiffness, or neuropathic pain. 
The chronic stage (after the third month) is defined by the absence of return to pre- 
existing condition more than 3 months after the onset of CHIK. The chronic phase can 
last a few months to several years (more than 6 years for a small group of patients in 
Reunion Island). The observed clinical symptoms are the same as in the post-acute 
stage. It is common to observe painful rebounds on joints used too strongly consid- 
ering their post-CHIK inflammatory condition. The diagnostic approach is to qualify the 
nosology of each patient according to the presence or absence of inflammatory 
symptoms (arthritis, enthesitis, tenosynovitis, inflammatory arthralgia) and the number 
of joints involved (polyarticular if 4 joints). 
In infected newborns, symptoms generally develop on days 3 to 7 of life with fever, 
rash, and peripheral edema. Pathology typically reveals a bicytopenia, increased pro- 
thrombin time, and aspartate aminotransferase level. The presentation in infants is 
subsequently complicated by seizures, hemorrhagic syndrome, hemodynamic disor- 
ders, and myocardial dysfunction.59,87 Neonatal symptoms range from mild presenta- 
tion (43%) to severe infection with encephalitis (53%)59 that requires intensive care. 
Fever and acute respiratory distress have also been reported.88 Neurologic complica- 
tions can have severe effects on postnatal neurologic development, such as lower 
development quotient at age of 2 years, and moderate to severe global neurodevelop- 
mental delay.89 
Atypical Features and Complications 
Complications of the cardiovascular, renal, respiratory, hepatic gastrointestinal, and 
adrenal systems are associated with the infection and referred to as atypical features 
(Table 4). As reported during the Reunion Island outbreak in 2005, the proportion of 
atypical cases was 0.3%. Atypical cases were defined as patients with clinical presen- 
tation of fever, arthralgia, and other atypical signs. The median age of the cases was 
70 years. Of the 610 atypical cases, 546 (89%) had underlying medical conditions, 479 
(78%) were on medication before hospitalization. However, the involvement of the 
central nervous system is the most common complication of CHIK infection. Neuro- 
logic disease after CHIKV infection was first reported during an outbreak in 1964 in 
Madras, India.90 In 2 studies investigating manifestations of CHIKV in patients 
requiring intensive care, a neurologic disorder was the primary issue in 61%91 and 
79%.92 Given the large spectrum of neurologic disease and scarce epidemiologic data, 
estimating the incidence of neurologic disease among all systemically 
 
 
Table 4 
Clinical features of CHIKV: complications 
 
Organ/System Complication(s) 
Nervous system Frequent 
Encephalopathy and meningitis 
Myelopathy and myelitis 
Encephalomyelopathy 
Myeloneuropathy 
Encephalomyeloneuropathy 
Guillain-Barré  syndrome 
Acute disseminated encephalomyelitis 
Neonatal hypotonia 
Optic neuritis 
Less frequent 
Seizures 
Sensorineural hearing loss 
Stroke 
Cerebellitis 
Third nerve palsy 
Encephalopathy 
Behavioral changes 
Carpal tunnel syndrome 
  Bilateral ophthalmoplegia  
Cardiovascular 
system 
Heart  failure 
Arrhythmias 
Myocarditis/pericarditis 
Blood pressure instability 
  Acute myocardial infarction  
Ocular Conjunctivitis, episcleritis, nongranulomatous anterior uveitis, 
granulomatous anterior uveitis 
Keratitis, retinitis with vitritis, bilateral retinitis 
Multifocal choroiditis, optic neuritis, retrobulbar neuritis 
  Exudative retinal detachment, pan-uveitis  
Other organ 
involvement 
Pre-renal failure 
Exacerbation of chronic renal failure 
Pneumonia and respiratory failure 
Hepatic insufficiency, subacute hepatitis 
Bullous dermatosis 
Pancreatitis 
Syndrome of inappropriate antidiuretic hormone secretion 
Hypoadrenalism 
 
symptomatic CHIKV infections is difficult. In 1 study from the 2006 Indian outbreak, 18 
(4.4%) of 405 suspected cases of CHIKV attending the recruiting hospital over 
3 months developed neurologic complications.90 An epidemiologic study  of  the  2005 
to 2006 Reunion Island outbreak found approximately 0.3% of all CHIKV infec- tions 
resulted in atypical cases,93 of which 24.1% of the adults presented with abnormal 
neurology. Thus, approximately 0.1% (1 case per 1000) of all CHIKV infec- tions 
developed neurologic disease. It has been observed that severe complications of 
CHIKV typically arise in patients with comorbidities. Studies from Reunion Island and 
from India show that underlying diseases play a role in neurologic disorders   and other 
complication but are not an indispensable requisite. Age has been reported as a 
significant risk factor for severe manifestations in the elderly (>65 years)90,93 and in 
infants.94 
 
 
A recent systematic review77 described the frequency of reported neurologic syn- 
dromes and diseases. The most frequent are encephalopathy and encephalitis, 
myelopathy and myelitis, Guillain-Barre´ syndrome, acute disseminated encephalomy- 
elitis, neonatal hypotonia, and neuro-ocular disease. Other manifestations are 
described less frequently, such as behavioral changes, seizure with and without fever, 
stroke, cerebellitis, meningism, third nerve palsy, encephalopathy, and bilateral total 
ophthalmoplegia. 
Mortality 
Although morbidity is debilitating, CHIKV mortality rates are low. As with most viral ill- 
nesses, people at a higher risk for more severe disease include the newborn, the 
elderly, and those with comorbid illnesses such as diabetes, heart disease, chronic 
liver and kidney disease, and human immunodeficiency virus. An increase in mortality 
has been observed in the last epidemics, probably as a result of neurologic disorders 
mainly in neonates, immunocompromised patients, and the elderly.55,63,95 In Europe, 
the case fatality rate was 2.5 per 1000 clinical cases,30 lower than that reported in the 
2007 outbreak in Italy (0.5%) but consistent with that reported from Reunion Island (1 
death per 1000 clinical cases).27,96 
 
LABORATORY DIAGNOSIS 
 
Several laboratory tests are available for diagnosing CHIK using serum or plasma to 
detect the virus, viral nucleic acid, or virus-specific immunoglobulin (Ig) IgM, and 
neutralizing antibodies. Given the high viral load during viremia, CHIKV viral RNA can 
be detected during the first 5 to 8 days of illness using commercial tests with high 
sensitivity and specificity. The choice between the types of tests is dictated by the 
timing of the sampling with respect to the beginning of the symptoms and the vol- ume 
of the samples available. 
Serologic Tests 
CHIKV IgM antibodies normally develop toward the end of the first week of illness, and 
to definitively rule out the diagnosis, convalescent-phase samples should be obtained 
from patients whose acute-phase samples test negative. Serologic diagnosis of CHIK 
is made by detecting CHIKV-specific IgM in serum samples for 5 to 7 days after symp- 
tom onset, or by demonstrating a 4-fold increase (or seroconversion) of CHIK-specific 
IgG antibody titers in a pair of serum samples at least 15 days apart (acute and conva- 
lescent phase of the disease). IgM antibodies specific for CHIKV may persist for up to 
1 year, particularly in patients with long-term arthralgia, but typically persist for 3 to   4 
months. The specific CHIKV IgG can be detected for many years after initial infec- tion. 
Serologic cross-reactions and false-positive tests have been reported due to infection 
with closely related alphaviruses belonging to the Semliki forest virus. An enzyme-
linked immunosorbent assay may confirm the presence of IgM and IgG anti-CHIKV 
antibodies. IgM antibody levels are highest 3 to 5 weeks after the onset of illness and 
persist for about 2 months. Samples collected during the first week after the onset of 
symptoms should be tested by both serologic and virologic methods (reverse 
transcriptase-polymerase chain reaction [RT-PCR]). 
Molecular Diagnostic Tests 
PCR detection of specific CHIKV RNA can be detected by RT-PCR in serum or 
plasma/EDTA samples obtained from patients during the acute phase of infection 
(typically s7 days after the onset of symptoms). CHIKV infection causes high levels 
 
 
of viremia, which usually last for 4 to 6 days after the onset of symptoms. This is a 
favorable situation for diagnosis. Real-time RT-PCR is the ideal test for the diagnosis 
of CHIKV infections in the acute phase of infection. RT-PCR can typically be per- 
formed within the first 7 days of symptom onset to confirm CHIKV infection. The virus 
may be isolated from the blood during the first few days of infection. Various RT-PCR 
methods are available but are of variable sensitivity. Some are suited to clinical diag- 
nosis. RT-PCR products from clinical samples may also be used for genotyping of the 
virus, allowing comparisons with virus samples from various geographic sources. 
Viral culture may detect the virus in the first 3 days of illness; however, CHIKV should 
be handled under biosafety level 3 conditions. 
 
TREATMENT 
Supportive Treatment 
There is no effective antiviral treatment, and thus treatment of CHIK is supportive and 
symptomatic. It should be adapted to the clinical context and risk groups aimed at 
controlling fever and pain, treating dehydration, organ support, and preventing iatro- 
genic complications and functional impairment. Infection control procedures should be 
instituted to reduce the risk of iatrogenic infection to health care and laboratory 
workers. 
Analgesics 
Analgesia based on acetaminophen therapy is preferred. Using nonsteroidal anti-  
inflammatory drugs (NSAIDs) and salicylates is not recommended in the 14 days after 
onset of the disease because of the risk of bleeding complications related to dengue 
fever unless this diagnosis is ruled out, and Reye syndrome induced by aspirin. Using 
analgesics (weak opioids) is required if acetaminophen is not effective: tramadol alone 
or in combination with acetaminophen. 
The treatment of the post-acute stage should be based primarily on analgesics 
(stages 1 and 2), neuropathic drugs, and NSAIDs. 
Nonsteroidal Anti-Inflammatory Drugs 
No NSAID class has demonstrated superiority of effectiveness on post-CHIK symp- 
toms. A local anti-inflammatory therapy (topical or infiltration) should be prescribed  in 
case of tenosynovitis, bursitis, tunnel syndrome, capsulitis, or synovitis inade- quately 
controlled by oral treatment, to limit the therapeutic excess. The risk of drug toxicity by 
overdose (self-medication) or drug interaction is high for acetaminophen as well as for 
other analgesics, anti-inflammatory drugs, long-term treatments, and traditional 
medicines used for self-medication.86 
Use of Steroids 
The use of corticosteroids is not recommended. Steroids may also cause severe 
rebound of arthritis and tenosynovitis. Systemic corticosteroids should be used only 
for inflammatory polyarticular presentations, especially when associated with teno- 
synovitis, active synovitis, or in case of resistance or contraindication to NSAIDs. 
Newer Therapies 
Off-label use of other US Food and Drug Administration-approved drugs in a thera- 
peutic manner has been proposed and is under consideration. In animal models of 
CHIKV infection, prophylaxis with CHIKV IgG or CHIKV-specific monoclonal anti- 
bodies was found to be protective,97 suggesting that antibody-based therapies may be 
a promising disease prevention strategy for individuals who are at risk for severe 
 
 
CHIKV infection. In cell-based screens of compounds against CHIKV infection, several 
drugs with antiviral activity have been identified, some of which target distinct steps in 
the CHIKV replication cycle. These include chloroquine98 and chlorpromazine,99 which 
affect virus entry. Harringtonine and  homoharringtonine100 have been found  to affect 
viral protein translation. Others, including trigocherriolide A,101 ribavirin,102 interferon-
alpha,103 apigenin, and silybin99 affect virus replication. More extensive pre- clinical 
evaluation of these and other identified drugs in animal models of CHIKV dis- ease are 
necessary before they are proposed for use in humans. 
 
PREVENTION 
 
At present, there is no effective vaccine against CHIKV infection. The proximity of 
mosquito vector breeding sites to human habitation is a significant risk factor for 
CHIKV. Prevention and control rely on reducing the number of natural and artificial 
water-filled container habitats that support breeding of the mosquitoes. This requires 
mobilization of affected communities. 
Vector Control and Breeding Reservoirs 
Vector control depends on reducing the number of natural and artificial water-filled 
container habitats that support breeding of mosquitoes. Accumulation of stagnant wa- 
ter should be prevented. Water in vases should be changed once a week. Using saucers 
underneath flower pots should be avoided. Water containers should be tightly covered. 
Air-conditioner drip trays should be free of stagnant water. All used cans and bottles 
should be placed in covered dustbins. During outbreaks, insecticides may be sprayed 
to kill flying mosquitoes, applied to surfaces in and around containers where the 
mosquitoes land, and used to treat water in containers to kill the immature larvae. 
Clothing and Insect Repellants 
For protection during CHIK outbreaks, clothing that minimizes skin exposure to the 
day-biting vectors is advised. Repellents can be applied to exposed skin or to clothing 
in strict accordance with product label instructions. Repellents should contain DEET 
(N,N-diethyl-3-methylbenzamide), IR3535 (3-[N-acetyl-N-butyl]-aminopropionic acid 
ethyl ester), or icaridin (1-piperidinecarboxylic acid, 2-(2-hydroxyethyl)-1-methylpro- 
pylester). For those who sleep during the daytime, particularly young children, or  sick 
or older people, insecticide-treated mosquito nets afford good protection. Mos- quito 
coils or other insecticide vaporizers may also reduce indoor biting. 
Miscellaneous Advice to Travelers 
Basic precautions should be taken by people traveling to risk areas, and these include 
use of repellents, wearing long sleeves and pants, and ensuring rooms are fitted with 
screens to prevent mosquitoes from entering bedrooms. General measures on pre- 
venting mosquito-borne diseases include wearing loose, light-colored, long-sleeved 
tops and trousers, and use of insect repellent on exposed parts of the body and 
clothing. Use of fragrant cosmetics or skin care products should be avoided. Clothing, 
tents, and bed nets should be treated with permethrin (an insecticide). Travelers who 
return from affected areas and feel unwell, for example, have a fever, should be advised 
to seek medical advice promptly and provide travel details to the doctor. 
Vaccines 
After the reemergence of CHIKV in 2004 and its rapid expansion throughout the Indian 
Ocean and Southeast Asia, and unexpected autochthonous transmission in Europe in 
 
 
2007 and later in 2017, there has been renewed interest in developing a vaccine 
against CHIKV. Several approaches have been used for the development of CHIKV 
vaccines, including noninfectious104 and infectious DNA vaccines,105 viruslike parti- 
cles (VLP), and inactivated virus. Live attenuated vaccines under development include 
rationally attenuated alphavirus chimeras106 and deletion mutants107; a vesicular 
stomatitis-vectored vaccine108; and an internal ribosome entry site-modified CHIKV 
strain.109 To date, 3 CHIKV vaccines have progressed to clinical trials. The strain 
181/clone25, developed by the US Army in the 1980s,110 proved highly immunogenic 
but mildly reactogenic in phase 2 trials.111 A VLP vaccine produced by expression of 
the CHIKV structural proteins in vertebrate cells demonstrated efficacy in preclinical 
studies in mice or Rhesus macaques.112 Phase 1 clinical studies showed strong 
immunogenicity after 2 to 3 doses. Currently, this vaccine is not licensed to a commer- 
cial partner. A CHIKF vaccine in advanced stages of clinical development uses an 
attenuated measles virus strain as a vector to express the CHIKV structural pro- 
teins.113 In a phase 1 trial, this vaccine was well tolerated and induced neutralizing an- 
tibodies in 44% of volunteers receiving a single low dose, 92% receiving a medium 
dose, and 90% receiving a high dose. A booster raised seroconversion to 100%,   and 
immunogenicity was not affected by pre-existing anti-measles immunity. This vaccine 
is now in a phase 2 trial.114 
 
  
 
 
 
 
Table 5 
CHIKV: addressing gaps in knowledge and strengthening public health preparedness 
Knowledge Gaps/Needs Actions Required 
Understanding the epidemiology and 
pathogenesis of CHIKV across geographic 
settings 
Appropriately funded, well-designed 
longitudinal and cross-sectional clinical, 
pathogenesis, and epidemiologic studies 
of sylvatic, rural, and urban cycles (animal 
 and human studies) 
 
The spectrum of the vertebrate intermediate 
hosts 
Evaluate the possibility of endemic 
circulation of CHIKV by means of virus 
identification at the human-animal  
interface
  
Prevalent mosquito vectors and their 
behavior 
 
Improved diagnostic, treatment, prognostic, 
prevention, and surveillance tools 
Integrating entomologic and human 
surveillance 
 
More investments into development and 
evaluation of: 
a. Newer, affordable, field-friendly rapid 
diagnostic tests and sequencing platforms 
b. New biomarkers of disease progression 
c. Newer treatments (antivirals, 
immunotherapies, and host-directed 
therapies) 
 d.  New vaccines 
 
Defining the animal and environmental host 
reservoirs 
 
Customization of vector control measures 
adapted to local culture and norms in the 
context of the population behavior 
Cross-sectional and longitudinal studies at 
the human-animal interface 
 
Close collaboration between medical and 
social science/anthropologists/animal- 
human-environmental sectors and local 
communities 
 
Establish the cocirculation of other 
arboviruses 
 
Lack of understanding of factors underlying 
the pathogenesis of organ involvement 
and complications; eg, acute and persisting 
synovial pathology and arthritis; and of 
maternal-infant transmission and infection 
rate of newborns 
Appropriate use of serology and 
metagenomics analysis during outbreaks 
 
Longitudinal cohort studies during 
outbreaks 
New surveillance tools, early warning 
systems, and real-time data management 
The integration of different surveillance 
tools and the combination with 
entomologic surveillance in a One Health 
dedicated surveillance system should 
facilitate the detection, response, and 
control of arboviruses spreading, including 
CHIKV 
 
 
 
SUMMARY 
 
Several challenges are involved in the development of tools and strategies for preven- 
tion of zoonotic and re-emerging infections with epidemic potential, including CHIK 
(Table 5): early identification of human cases, developing rapid point of care diagnos- 
tics, and effective treatments and vaccines. The establishment of more effective 
collaborative research networks involving different disciplines, such as medical ento- 
mologists, virologists, veterinarians, infectious diseases clinicians, social science ex- 
perts, anthropologists, community leaders, and policymakers, is required to enable 
more effective definition of host reservoirs, improving outbreak response and control 
activities. Given the unpredictability and paucity of CHIK and other zoonotic out- 
breaks, public health response and preparedness should be ready to perform research 
immediately during an outbreak, allowing for evaluation of existing and newer 
diagnostics, treatments, and vaccines. These are being addressed through increasing 
research capacity during interepidemic periods with an integrated One Health (hu- 
man-environmental-animal health) approach115,116 to assist in rapid investigations of 
zoonotic outbreaks and development of local capacity to improve national public health 
institutions. 
 
DISCLOSURE 
 
All authors have an interest in global public health and emerging and re-emerging 
infections. All authors are part of the PANDORA-ID-NET Consortium (EDCTP reg/grant 
RIA2016E-1609) funded by the European and Developing Countries Clinical Trials 
Partnership (EDCTP2) program, which is supported under Horizon 2020, the European 
Union’s Framework Programme for Research and Innovation. A. Zumla is in receipt of 
a National Institutes of Health Research (NIHR) senior investigator award. F. Ntoumi 
and A. Zumla acknowledge support from EDCTP (CANTAM2). F. Vairo and G. Ippolito 
acknowledge financial support from the Italian Ministry of Health, grants to Ricerca 
Corrente linea 1 to National Institute for Infectious Diseases, Lazzaro Spallanzani, 
IRCCS. 
 
REFERENCES 
 
1. Diallo M, Thonnon J, Traore-Lamizana M, et al. Vectors of Chikungunya virus in 
Senegal: current data and transmission cycles. Am J Trop Med Hyg 1999;60: 
281–6. 
2. Mason PJ, Haddow AJ. An epidemic of virus disease in Southern Province, Tan- 
ganyika Territory, in 1952-53; an additional note on Chikungunya virus isolations 
and serum antibodies. Trans R Soc Trop Med Hyg 1957;51:238–40. 
 
 
3. Ross RW. The Newala epidemic. III. The virus: isolation, pathogenic properties 
and relationship to the epidemic. J Hyg (Lond) 1956;54:177–91. 
4. Weaver SC, Forrester NL. Chikungunya: evolutionary history and recent 
epidemic spread. Antiviral Res 2015;120:32–9. 
5. Weinbren MP. The occurrence of Chikungunya virus in Uganda. II. In man on the 
Entebbe peninsula. Trans R Soc Trop Med Hyg 1958;52:258–9. 
6. Powers AM, Brault AC, Tesh RB, et al. Re-emergence of Chikungunya and 
O’nyong-nyong viruses: evidence for distinct geographical lineages and distant 
evolutionary relationships. J Gen Virol 2000;81:471–9. 
7. Volk SM, Chen R, Tsetsarkin KA, et al. Genome-scale phylogenetic analyses of 
chikungunya virus reveal independent emergences of recent epidemics and 
various evolutionary rates. J Virol 2010;84:6497–504. 
8. Tsetsarkin KA, Chen R, Leal G, et al. Chikungunya virus emergence is con- 
strained in Asia by lineage-specific adaptive landscapes. Proc Natl Acad Sci   U 
S A 2011;108:7872–7. 
9. Nunes MR, Faria NR, de Vasconcelos JM, et al. Emergence and potential for 
spread of Chikungunya virus in Brazil. BMC Med 2015;13:102. 
10. Mourya DT, Thakare JR, Gokhale MD, et al. Isolation of chikungunya virus from 
Aedes aegypti mosquitoes collected in the town of Yawat, Pune District, Maha- 
rashtra State, India. Acta Virol 2001;45:305–9. 
11. Rausalu K, Utt A, Quirin T, et al. Chikungunya virus infectivity, RNA replication 
and non-structural polyprotein processing depend on the nsP2 protease’s  active 
site cysteine residue. Sci Rep 2016;6:37124. 
12. Metz SW, Pijlman GP. Production of Chikungunya virus-like particles and subunit 
vaccines in insect cells. Methods Mol Biol 2016;1426:297–309. 
13. Khan AH, Morita K, Parquet MD, et al. Complete nucleotide sequence of chikun- 
gunya virus and evidence for an internal polyadenylation site. J Gen Virol 2002; 
83:3075–84. 
14. Voss JE, Vaney MC, Duquerroy S, et al. Glycoprotein organization of Chikungu- 
nya virus particles revealed by X-ray crystallography. Nature 2010;468:709–12. 
15. Snyder AJ, Sokoloski KJ, Mukhopadhyay S. Mutating conserved cysteines in the 
alphavirus e2 glycoprotein causes virus-specific assembly defects. J Virol 2012; 
86:3100–11. 
16. Melton JV, Ewart GD, Weir RC, et al. Alphavirus 6K proteins form ion channels. 
J Biol Chem 2002;277:46923–31. 
17. Snyder JE, Kulcsar KA, Schultz KL, et al. Functional characterization of the al- 
phavirus TF protein. J Virol 2013;87:8511–23. 
18. Solignat M, Gay B, Higgs S, et al. Replication cycle of chikungunya: a re- 
emerging arbovirus. Virology 2009;393:183–97. 
19. Lum FM, Ng LF. Cellular and molecular mechanisms of chikungunya pathogen- 
esis. Antiviral Res 2015;120:165–74. 
20. Rupp JC, Sokoloski KJ, Gebhart NN, et al. Alphavirus RNA synthesis and non- 
structural protein functions. J Gen Virol 2015;96:2483–500. 
21. Powers AM. Vaccine and therapeutic options to control Chikungunya virus. Clin 
Microbiol Rev 2017;31 [pii:e00104-16]. 
22. Fortuna C, Remoli ME, Rizzo C, et al. Imported arboviral infections in Italy, July 
2014-October 2015: a National Reference Laboratory report. BMC Infect Dis 
2017;17:216. 
23. Wahid B, Ali A, Rafique S, et al. Global expansion of chikungunya virus: map- 
ping the 64-year history. Int J Infect Dis 2017;58:69–76. 
 
 
24. Sergon K, Yahaya AA, Brown J, et al. Seroprevalence of Chikungunya virus 
infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med 
Hyg 2007;76:1189–93. 
25. Josseran L, Paquet C, Zehgnoun A, et al. Chikungunya disease outbreak, 
Reunion Island. Emerg Infect Dis 2006;12:1994–5. 
26. Grandadam M, Caro V, Plumet S, et al. Chikungunya virus, southeastern France. 
Emerg Infect Dis 2011;17:910–3. 
27. Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an 
outbreak in a temperate region. Lancet 2007;370:1840–6. 
28. Delisle E, Rousseau C, Broche B, et al. Chikungunya outbreak in Montpellier, 
France, September to October 2014. Euro Surveill 2015;20. https://doi.org/10. 
2807/1560-7917.es2015.20.17.21108. 
29. Calba C, Guerbois-Galla M, Franke F, et al. Preliminary report of an autochtho- 
nous chikungunya outbreak in France, July to September 2017. Euro Surveill 
2017;22(39). https://doi.org/10.2807/1560-7917.ES.2017.22.39.17-00647. 
30. Vairo F, Mammone A, Lanini S, et al. Local transmission of chikungunya in Rome 
and the Lazio region, Italy. PLoS One 2018;13:e0208896. 
31. Bordi L, Carletti F, Lalle E, et al. Molecular characterization of autochthonous 
Chikungunya cluster in Latium region, Italy. Emerg Infect Dis 2018;24(1). 
https://doi.org/10.3201/eid2401.171605. 
32. Diallo D, Sall AA, Buenemann M, et al. Landscape ecology of sylvatic chikungu- 
nya virus and mosquito vectors in southeastern Senegal. PLoS Negl Trop Dis 
2012;6:e1649. 
33. Jupp PG, McIntosh BM. Aedes furcifer and other mosquitoes as vectors of chi- 
kungunya virus at Mica, northeastern Transvaal, South Africa. J Am Mosq Con- 
trol Assoc 1990;6:415–20. 
34. Coffey LL, Failloux AB, Weaver SC. Chikungunya virus-vector interactions. Vi- 
ruses 2014;6:4628–63. 
35. Gubler DJ. The global emergence/resurgence of arboviral diseases as public 
health problems. Arch Med Res 2002;33:330–42. 
36. Lounibos LP. Invasions by insect vectors of human disease. Annu Rev Entomol 
2002;47:233–66. 
37. Powers AM, Logue CH. Changing patterns of chikungunya virus: re-emergence 
of a zoonotic arbovirus. J Gen Virol 2007;88:2363–77. 
38. Schuffenecker I, Iteman I, Michault A, et al. Genome microevolution of chikungu- 
nya viruses causing the Indian Ocean outbreak. PLoS Med 2006;3:e263. 
39. Tsetsarkin KA, Vanlandingham DL, McGee CE, et al. A single mutation in chikun- 
gunya virus affects vector specificity and epidemic potential. PLoS Pathog 
2007;3:e201. 
40. Vashishtha M, Phalen T, Marquardt MT, et al. A single point mutation controls the 
cholesterol dependence of Semliki Forest virus entry and exit. J Cell Biol 1998; 
140:91–9. 
41. Venturi G, Di Luca M, Fortuna C, et al. Detection of a chikungunya outbreak in 
Central Italy, August to September 2017. Euro Surveill 2017;22(39). https://doi. 
org/10.2807/1560-7917.ES.2017.22.39.17-00646. 
42. Bordi L, Carletti F, Castilletti C, et al. Presence of the A226V mutation in autoch- 
thonous and imported Italian chikungunya virus strains. Clin Infect Dis 2008;47: 
428–9. 
43. Tsetsarkin KA, Chen R, Yun R, et al. Multi-peaked adaptive landscape for chi- 
kungunya virus evolution predicts continued fitness optimization in Aedes albo- 
pictus mosquitoes. Nat Commun 2014;5:4084. 

 
 
44. Tsetsarkin KA, McGee CE, Volk SM, et al. Epistatic roles of E2 glycoprotein mu- 
tations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti 
mosquitoes. PLoS One 2009;4:e6835. 
45. Horwood PF, Buchy P. Chikungunya. (Special Issue: New developments in major 
vector-borne diseases. Part II: important diseases for veterinarians.). Sci Tech 
Rev Off Int Epiz 2015;34:479–89. 
46. Mavale M, Parashar D, Sudeep A, et al. Venereal transmission of chikungunya 
virus by Aedes aegypti mosquitoes (Diptera: Culicidae). Am J Trop Med Hyg 
2010;83:1242–4. 
47. Agarwal A, Dash PK, Singh AK, et al. Evidence of experimental vertical trans- 
mission of emerging novel ECSA genotype of Chikungunya Virus in Aedes ae- 
gypti. PLoS Negl Trop Dis 2014;8:e2990. 
48. Chompoosri J, Thavara U, Tawatsin A, et al. Vertical transmission of Indian 
Ocean Lineage of chikungunya virus in Aedes aegypti and Aedes albopictus 
mosquitoes. Parasit Vectors 2016;9:227. 
49. Jain J, Kushwah RBS, Singh SS, et al. Evidence for natural vertical transmission 
of chikungunya viruses in field populations of Aedes aegypti in Delhi and Har- 
yana states in India-a preliminary report. Acta Trop 2016;162:46–55. 
50. Furuya-Kanamori L, Liang S, Milinovich G, et al. Co-distribution and co-infection 
of chikungunya and dengue viruses. BMC Infect Dis 2016;16:84. 
51. Boga JA, Alvarez-Arguelles ME, Rojo-Alba S, et al. Simultaneous detection of 
Dengue virus, Chikungunya virus, Zika virus, Yellow fever virus and West Nile 
virus. J Virol Methods 2019;268:53–5. 
52. Appassakij H, Khuntikij P, Kemapunmanus M, et al. Viremic profiles in asymp- 
tomatic and symptomatic chikungunya fever: a blood transfusion threat? Trans- 
fusion 2013;53:2567–74. 
53. Brouard C, Bernillon P, Quatresous I, et al. Estimated risk of Chikungunya viremic 
blood donation during an epidemic on Reunion Island in the Indian  Ocean, 2005 
to 2007. Transfusion 2008;48:1333–41. 
54. Liumbruno GM, Calteri D, Petropulacos K, et al. The Chikungunya epidemic in 
Italy and its repercussion on the blood system. Blood Transfus 2008;6:199–210. 
55. Kee AC, Yang S, Tambyah P. Atypical chikungunya virus infections in immuno- 
compromised patients. Emerg Infect Dis 2010;16:1038–40. 
56. Dalla Gasperina D, Balsamo ML, Garavaglia SD, et al. Chikungunya infection in 
a human immunodeficiency virus-infected kidney transplant recipient returning to 
Italy from the Dominican Republic. Transpl Infect Dis 2015;17:876–9. 
57. Girão ES, Rodrigues Dos Santos BG, do Amaral ES, et al. Chikungunya infection 
in solid organ transplant recipients. Transpl Proc 2017;49:2076–81. 
58. Couderc T, Gangneux N, Chrétien F, et al. Chikungunya virus infection of corneal 
grafts. J Infect Dis 2012;206:851–9. 
59. Gérardin P, Barau G, Michault  A, et  al. Multidisciplinary prospective study of 
mother-to-child  chikungunya  virus  infections  on  the  island  of  La  Réunion. 
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